You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameLomefloxacin
Accession NumberDB00978  (APRD01076)
TypeSmall Molecule
GroupsApproved
DescriptionLomefloxacin is a fluoroquinolone antibiotic, used to treat bacterial infections including bronchitis and urinary tract infections. It is also used to prevent urinary tract infections prior to surgery.
Structure
Thumb
Synonyms
(+-)-1-Ethyl-6,8-difluoro-1,4-dihydro-7-(3-methyl-1-piperazinyl)-4-oxo-3-quinolinecarboxylic acid
1,4-Dihydro-6,8-difluoro-1-ethyl-7-(3-methyl-1-piperazinyl)-4-oxo-3-quinolinecarboxylic acid
LFLX
Lomefloxacine
Lomefloxacino
Lomefloxacinum
External Identifiers Not Available
Approved Prescription ProductsNot Available
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
BareonNot Available
MaxaquinNot Available
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Lomefloxacin hydrochloride
Thumb
  • InChI Key: KXEBLAPZMOQCKO-UHFFFAOYNA-N
  • Monoisotopic Mass: 387.116125638
  • Average Mass: 387.809
DBSALT000795
Categories
UNIIL6BR2WJD8V
CAS number98079-51-7
WeightAverage: 351.3479
Monoisotopic: 351.139447899
Chemical FormulaC17H19F2N3O3
InChI KeyZEKZLJVOYLTDKK-UHFFFAOYSA-N
InChI
InChI=1S/C17H19F2N3O3/c1-3-21-8-11(17(24)25)16(23)10-6-12(18)15(13(19)14(10)21)22-5-4-20-9(2)7-22/h6,8-9,20H,3-5,7H2,1-2H3,(H,24,25)
IUPAC Name
1-ethyl-6,8-difluoro-7-(3-methylpiperazin-1-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid
SMILES
CCN1C=C(C(O)=O)C(=O)C2=CC(F)=C(N3CCNC(C)C3)C(F)=C12
Pharmacology
IndicationFor the treatment of bacterial infections of the respiratory tract (chronic bronchitis) and urinary tract, and as a pre-operative prophylactic to prevent urinary tract infection caused by: S.pneumoniae, H.influenzae, S.aureus, P.aeruginosa, E. cloacae, P. mirabilis, C. civersus, S. asprphyticus, E.coli, and K.pneumoniae.
Structured Indications Not Available
PharmacodynamicsLomefloxacin is a fluoroquinolone antibiotic used to treat chronic bronchitis, as well as complicated and uncomplicated urinary tract infections. It is also used as a prophylactic or preventative treatment to prevent urinary tract infections in patients undergoing transrectal or transurethral surgical procedures. Flouroquinolones such as lomefloxacin possess excellent activity against gram-negative aerobic bacteria such as E.coli and Neisseria gonorrhoea as well as gram-positive bacteria including S. pneumoniae and Staphylococcus aureus. They also posses effective activity against shigella, salmonella, campylobacter, gonococcal organisms, and multi drug resistant pseudomonas and enterobacter.
Mechanism of actionLomefloxacin is a bactericidal fluoroquinolone agent with activity against a wide range of gram-negative and gram-positive organisms. The bactericidal action of lomefloxacin results from interference with the activity of the bacterial enzymes DNA gyrase and topoisomerase IV, which are needed for the transcription and replication of bacterial DNA. DNA gyrase appears to be the primary quinolone target for gram-negative bacteria. Topoisomerase IV appears to be the preferential target in gram-positive organisms. Interference with these two topoisomerases results in strand breakage of the bacterial chromosome, supercoiling, and resealing. As a result DNA replication and transcription is inhibited.
TargetKindPharmacological actionActionsOrganismUniProt ID
DNA gyrase subunit AProteinyes
inhibitor
Haemophilus influenzae (strain ATCC 51907 / DSM 11121 / KW20 / Rd)P43700 details
DNA topoisomerase 4 subunit AProteinyes
inhibitor
Haemophilus influenzae (strain ATCC 51907 / DSM 11121 / KW20 / Rd)P43702 details
DNA topoisomerase 2-alphaProteinunknown
inhibitor
HumanP11388 details
Related Articles
AbsorptionRapid and nearly complete with approximately 95% to 98% of a single oral dose being absorbed.
Volume of distributionNot Available
Protein binding10%
Metabolism

Minimally metabolized although 5 metabolites have been identified in human urine. 65% appears as the parent drug in urine and 9% as the glucuronide metabolite.

Route of eliminationThe urinary excretion of lomefloxacin was virtually complete within 72 hours after cessation of dosing, with approximately 65% of the dose being recovered as parent drug and 9% as its glucuronide metabolite.
Half life8 hours
Clearance
  • 271 mL/min/1.73 m2 [creatinine clearance of 110 mL/min/1.73 m2]
  • 31 mL/min/1.73 m2 [creatinine clearance of 0 mL/min/1.73 m2]
ToxicityAdverse reactions include peripheral neuropathy, nervousness, agitation, anxiety, and phototoxic events (rash, itching, burning) due to sunlight exposure.
Affected organisms
  • Enteric bacteria and other eubacteria
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
16-BromoepiandrosteroneThe risk or severity of adverse effects can be increased when 16-Bromoepiandrosterone is combined with Lomefloxacin.Investigational
19-norandrostenedioneThe risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Lomefloxacin.Experimental, Illicit
4-AndrostenedioneThe risk or severity of adverse effects can be increased when 4-Androstenedione is combined with Lomefloxacin.Experimental, Illicit
5-androstenedioneThe risk or severity of adverse effects can be increased when 5-androstenedione is combined with Lomefloxacin.Experimental, Illicit
AbirateroneThe serum concentration of Lomefloxacin can be increased when it is combined with Abiraterone.Approved
AcarboseLomefloxacin may increase the hypoglycemic activities of Acarbose.Approved, Investigational
AceclofenacAceclofenac may increase the neuroexcitatory activities of Lomefloxacin.Approved
AcenocoumarolLomefloxacin may increase the anticoagulant activities of Acenocoumarol.Approved
AcetovanilloneAcetovanillone may increase the neuroexcitatory activities of Lomefloxacin.Investigational
AcetyldigitoxinAcetyldigitoxin may decrease the cardiotoxic activities of Lomefloxacin.Approved
Acetylsalicylic acidAcetylsalicylic acid may increase the neuroexcitatory activities of Lomefloxacin.Approved, Vet Approved
AdapaleneAdapalene may increase the neuroexcitatory activities of Lomefloxacin.Approved
AlbiglutideLomefloxacin may increase the hypoglycemic activities of Albiglutide.Approved
AlclometasoneThe risk or severity of adverse effects can be increased when Alclometasone is combined with Lomefloxacin.Approved
AldosteroneThe risk or severity of adverse effects can be increased when Aldosterone is combined with Lomefloxacin.Experimental
AlogliptinLomefloxacin may increase the hypoglycemic activities of Alogliptin.Approved
Aluminum hydroxideAluminum hydroxide can cause a decrease in the absorption of Lomefloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Aluminum phosphateAluminum phosphate can cause a decrease in the absorption of Lomefloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Ambroxol acefyllinateThe metabolism of Ambroxol acefyllinate can be decreased when combined with Lomefloxacin.Experimental
AmcinonideThe risk or severity of adverse effects can be increased when Amcinonide is combined with Lomefloxacin.Approved
AminophyllineThe metabolism of Aminophylline can be decreased when combined with Lomefloxacin.Approved
AnecortaveThe risk or severity of adverse effects can be increased when Anecortave is combined with Lomefloxacin.Investigational
AnisodamineAnisodamine may increase the neuroexcitatory activities of Lomefloxacin.Investigational
AntipyrineAntipyrine may increase the neuroexcitatory activities of Lomefloxacin.Approved
AnvirzelAnvirzel may decrease the cardiotoxic activities of Lomefloxacin.Investigational
ApremilastApremilast may increase the neuroexcitatory activities of Lomefloxacin.Approved, Investigational
AzapropazoneAzapropazone may increase the neuroexcitatory activities of Lomefloxacin.Withdrawn
AzelastineAzelastine may increase the neuroexcitatory activities of Lomefloxacin.Approved
AzithromycinThe metabolism of Lomefloxacin can be decreased when combined with Azithromycin.Approved
BalsalazideBalsalazide may increase the neuroexcitatory activities of Lomefloxacin.Approved, Investigational
BcgThe therapeutic efficacy of Bcg can be decreased when used in combination with Lomefloxacin.Investigational
BeclomethasoneThe risk or severity of adverse effects can be increased when Beclomethasone is combined with Lomefloxacin.Investigational
Beclomethasone dipropionateThe risk or severity of adverse effects can be increased when Beclomethasone dipropionate is combined with Lomefloxacin.Approved, Investigational
BenoxaprofenBenoxaprofen may increase the neuroexcitatory activities of Lomefloxacin.Withdrawn
BetamethasoneThe risk or severity of adverse effects can be increased when Betamethasone is combined with Lomefloxacin.Approved, Vet Approved
Betulinic AcidBetulinic Acid may increase the neuroexcitatory activities of Lomefloxacin.Investigational
BevacizumabBevacizumab may increase the cardiotoxic activities of Lomefloxacin.Approved, Investigational
Bismuth SubcitrateBismuth Subcitrate can cause a decrease in the absorption of Lomefloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
BortezomibThe metabolism of Lomefloxacin can be decreased when combined with Bortezomib.Approved, Investigational
BromfenacBromfenac may increase the neuroexcitatory activities of Lomefloxacin.Approved
BromocriptineLomefloxacin may increase the hypoglycemic activities of Bromocriptine.Approved, Investigational
BucillamineBucillamine may increase the neuroexcitatory activities of Lomefloxacin.Investigational
BudesonideThe risk or severity of adverse effects can be increased when Budesonide is combined with Lomefloxacin.Approved
CabazitaxelThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Lomefloxacin.Approved
CaffeineThe metabolism of Lomefloxacin can be decreased when combined with Caffeine.Approved
CalciumCalcium can cause a decrease in the absorption of Lomefloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Nutraceutical
Calcium AcetateCalcium Acetate can cause a decrease in the absorption of Lomefloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Calcium carbonateCalcium carbonate can cause a decrease in the absorption of Lomefloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Calcium ChlorideCalcium Chloride can cause a decrease in the absorption of Lomefloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Calcium citrateCalcium citrate can cause a decrease in the absorption of Lomefloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Calcium glubionateCalcium glubionate can cause a decrease in the absorption of Lomefloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Calcium GluceptateCalcium Gluceptate can cause a decrease in the absorption of Lomefloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Calcium gluconateCalcium gluconate can cause a decrease in the absorption of Lomefloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Vet Approved
CanagliflozinLomefloxacin may increase the hypoglycemic activities of Canagliflozin.Approved
CarbamazepineThe metabolism of Lomefloxacin can be increased when combined with Carbamazepine.Approved, Investigational
CarprofenCarprofen may increase the neuroexcitatory activities of Lomefloxacin.Approved, Vet Approved, Withdrawn
CastanospermineCastanospermine may increase the neuroexcitatory activities of Lomefloxacin.Experimental
CelecoxibCelecoxib may increase the neuroexcitatory activities of Lomefloxacin.Approved, Investigational
ChloroquineChloroquine may increase the neuroexcitatory activities of Lomefloxacin.Approved, Vet Approved
ChlorpropamideLomefloxacin may increase the hypoglycemic activities of Chlorpropamide.Approved
CiclesonideThe risk or severity of adverse effects can be increased when Ciclesonide is combined with Lomefloxacin.Approved, Investigational
CitalopramThe metabolism of Lomefloxacin can be decreased when combined with Citalopram.Approved
ClobetasolThe risk or severity of adverse effects can be increased when Clobetasol is combined with Lomefloxacin.Investigational
Clobetasol propionateThe risk or severity of adverse effects can be increased when Clobetasol propionate is combined with Lomefloxacin.Approved
ClocortoloneThe risk or severity of adverse effects can be increased when Clocortolone is combined with Lomefloxacin.Approved
ClonixinClonixin may increase the neuroexcitatory activities of Lomefloxacin.Approved
ClotrimazoleThe metabolism of Lomefloxacin can be decreased when combined with Clotrimazole.Approved, Vet Approved
Cortisone acetateThe risk or severity of adverse effects can be increased when Cortisone acetate is combined with Lomefloxacin.Approved
CurcuminCurcumin may increase the neuroexcitatory activities of Lomefloxacin.Investigational
CyclophosphamideCyclophosphamide may increase the cardiotoxic activities of Lomefloxacin.Approved, Investigational
Cyproterone acetateThe serum concentration of Lomefloxacin can be decreased when it is combined with Cyproterone acetate.Approved, Investigational
D-LimoneneD-Limonene may increase the neuroexcitatory activities of Lomefloxacin.Investigational
DapagliflozinLomefloxacin may increase the hypoglycemic activities of Dapagliflozin.Approved
DeferasiroxThe serum concentration of Lomefloxacin can be increased when it is combined with Deferasirox.Approved, Investigational
dehydroepiandrosterone sulfateThe risk or severity of adverse effects can be increased when dehydroepiandrosterone sulfate is combined with Lomefloxacin.Investigational
DeslanosideDeslanoside may decrease the cardiotoxic activities of Lomefloxacin.Approved
DesoximetasoneThe risk or severity of adverse effects can be increased when Desoximetasone is combined with Lomefloxacin.Approved
Desoxycorticosterone acetateThe risk or severity of adverse effects can be increased when Desoxycorticosterone acetate is combined with Lomefloxacin.Approved
Desoxycorticosterone PivalateThe risk or severity of adverse effects can be increased when Desoxycorticosterone Pivalate is combined with Lomefloxacin.Experimental, Vet Approved
DexamethasoneThe risk or severity of adverse effects can be increased when Dexamethasone is combined with Lomefloxacin.Approved, Investigational, Vet Approved
Dexamethasone isonicotinateThe risk or severity of adverse effects can be increased when Dexamethasone isonicotinate is combined with Lomefloxacin.Vet Approved
DiclofenacDiclofenac may increase the neuroexcitatory activities of Lomefloxacin.Approved, Vet Approved
DicoumarolLomefloxacin may increase the anticoagulant activities of Dicoumarol.Approved
DidanosineThe serum concentration of Didanosine can be decreased when it is combined with Lomefloxacin.Approved
DiflorasoneThe risk or severity of adverse effects can be increased when Diflorasone is combined with Lomefloxacin.Approved
DiflunisalDiflunisal may increase the neuroexcitatory activities of Lomefloxacin.Approved
DifluocortoloneThe risk or severity of adverse effects can be increased when Difluocortolone is combined with Lomefloxacin.Approved
DifluprednateThe risk or severity of adverse effects can be increased when Difluprednate is combined with Lomefloxacin.Approved
DigitoxinDigitoxin may decrease the cardiotoxic activities of Lomefloxacin.Approved
DigoxinDigoxin may decrease the cardiotoxic activities of Lomefloxacin.Approved
DisopyramideLomefloxacin may increase the hypoglycemic activities of Disopyramide.Approved
DocetaxelThe risk or severity of adverse effects can be increased when Docetaxel is combined with Lomefloxacin.Approved, Investigational
DroxicamDroxicam may increase the neuroexcitatory activities of Lomefloxacin.Approved
DulaglutideLomefloxacin may increase the hypoglycemic activities of Dulaglutide.Approved
DuvelisibDuvelisib may increase the neuroexcitatory activities of Lomefloxacin.Investigational
DyphyllineThe metabolism of Dyphylline can be decreased when combined with Lomefloxacin.Approved
E6201E6201 may increase the neuroexcitatory activities of Lomefloxacin.Investigational
EbselenEbselen may increase the neuroexcitatory activities of Lomefloxacin.Investigational
EmpagliflozinLomefloxacin may increase the hypoglycemic activities of Empagliflozin.Approved
EpirizoleEpirizole may increase the neuroexcitatory activities of Lomefloxacin.Approved
EquileninThe risk or severity of adverse effects can be increased when Equilenin is combined with Lomefloxacin.Experimental
EquilinThe risk or severity of adverse effects can be increased when Equilin is combined with Lomefloxacin.Approved
EstroneThe risk or severity of adverse effects can be increased when Estrone is combined with Lomefloxacin.Approved
Estrone sulfateThe risk or severity of adverse effects can be increased when Estrone sulfate is combined with Lomefloxacin.Approved
EtanerceptEtanercept may increase the neuroexcitatory activities of Lomefloxacin.Approved, Investigational
Ethyl biscoumacetateLomefloxacin may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
EtodolacEtodolac may increase the neuroexcitatory activities of Lomefloxacin.Approved, Investigational, Vet Approved
EtofenamateEtofenamate may increase the neuroexcitatory activities of Lomefloxacin.Approved
EtoricoxibEtoricoxib may increase the neuroexcitatory activities of Lomefloxacin.Approved, Investigational
Evening primrose oilEvening primrose oil may increase the neuroexcitatory activities of Lomefloxacin.Approved
ExenatideLomefloxacin may increase the hypoglycemic activities of Exenatide.Approved, Investigational
exisulindexisulind may increase the neuroexcitatory activities of Lomefloxacin.Investigational
FenbufenFenbufen may increase the neuroexcitatory activities of Lomefloxacin.Approved
FenoprofenFenoprofen may increase the neuroexcitatory activities of Lomefloxacin.Approved
Ferric CarboxymaltoseThe serum concentration of Lomefloxacin can be decreased when it is combined with Ferric Carboxymaltose.Approved
Ferric CitrateThe serum concentration of Lomefloxacin can be decreased when it is combined with Ferric Citrate.Approved
Ferric pyrophosphateThe serum concentration of Lomefloxacin can be decreased when it is combined with Ferric pyrophosphate.Approved
FloctafenineFloctafenine may increase the neuroexcitatory activities of Lomefloxacin.Approved, Withdrawn
fluasteroneThe risk or severity of adverse effects can be increased when fluasterone is combined with Lomefloxacin.Investigational
FludrocortisoneThe risk or severity of adverse effects can be increased when Fludrocortisone is combined with Lomefloxacin.Approved
FluindioneLomefloxacin may increase the anticoagulant activities of Fluindione.Investigational
FlumethasoneThe risk or severity of adverse effects can be increased when Flumethasone is combined with Lomefloxacin.Approved, Vet Approved
FlunisolideThe risk or severity of adverse effects can be increased when Flunisolide is combined with Lomefloxacin.Approved, Investigational
FlunixinFlunixin may increase the neuroexcitatory activities of Lomefloxacin.Vet Approved
Fluocinolone AcetonideThe risk or severity of adverse effects can be increased when Fluocinolone Acetonide is combined with Lomefloxacin.Approved, Investigational, Vet Approved
FluocinonideThe risk or severity of adverse effects can be increased when Fluocinonide is combined with Lomefloxacin.Approved, Investigational
FluocortoloneThe risk or severity of adverse effects can be increased when Fluocortolone is combined with Lomefloxacin.Approved, Withdrawn
FluorometholoneThe risk or severity of adverse effects can be increased when Fluorometholone is combined with Lomefloxacin.Approved
FluprednideneThe risk or severity of adverse effects can be increased when Fluprednidene is combined with Lomefloxacin.Approved, Withdrawn
FluprednisoloneThe risk or severity of adverse effects can be increased when Fluprednisolone is combined with Lomefloxacin.Approved
FlurandrenolideThe risk or severity of adverse effects can be increased when Flurandrenolide is combined with Lomefloxacin.Approved
FlurbiprofenFlurbiprofen may increase the neuroexcitatory activities of Lomefloxacin.Approved, Investigational
Fluticasone furoateThe risk or severity of adverse effects can be increased when Fluticasone furoate is combined with Lomefloxacin.Approved
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Fluticasone Propionate is combined with Lomefloxacin.Approved
FluvoxamineThe metabolism of Lomefloxacin can be decreased when combined with Fluvoxamine.Approved, Investigational
FormestaneThe risk or severity of adverse effects can be increased when Formestane is combined with Lomefloxacin.Approved, Investigational, Withdrawn
GliclazideLomefloxacin may increase the hypoglycemic activities of Gliclazide.Approved
GlimepirideLomefloxacin may increase the hypoglycemic activities of Glimepiride.Approved
GlipizideLomefloxacin may increase the hypoglycemic activities of Glipizide.Approved
GlyburideLomefloxacin may increase the hypoglycemic activities of Glyburide.Approved
HE3286The risk or severity of adverse effects can be increased when HE3286 is combined with Lomefloxacin.Investigational
HigenamineHigenamine may increase the neuroexcitatory activities of Lomefloxacin.Investigational
HMPL-004HMPL-004 may increase the neuroexcitatory activities of Lomefloxacin.Investigational
HydrocortisoneThe risk or severity of adverse effects can be increased when Hydrocortisone is combined with Lomefloxacin.Approved, Vet Approved
IbuprofenIbuprofen may increase the neuroexcitatory activities of Lomefloxacin.Approved
IbuproxamIbuproxam may increase the neuroexcitatory activities of Lomefloxacin.Withdrawn
IcatibantIcatibant may increase the neuroexcitatory activities of Lomefloxacin.Approved
IndomethacinIndomethacin may increase the neuroexcitatory activities of Lomefloxacin.Approved, Investigational
IndoprofenIndoprofen may increase the neuroexcitatory activities of Lomefloxacin.Withdrawn
Insulin AspartLomefloxacin may increase the hypoglycemic activities of Insulin Aspart.Approved
Insulin DetemirLomefloxacin may increase the hypoglycemic activities of Insulin Detemir.Approved
Insulin GlargineLomefloxacin may increase the hypoglycemic activities of Insulin Glargine.Approved
Insulin GlulisineLomefloxacin may increase the hypoglycemic activities of Insulin Glulisine.Approved
Insulin HumanLomefloxacin may increase the hypoglycemic activities of Insulin Human.Approved, Investigational
Insulin LisproLomefloxacin may increase the hypoglycemic activities of Insulin Lispro.Approved
IronThe serum concentration of Lomefloxacin can be decreased when it is combined with Iron.Approved
Iron DextranThe serum concentration of Lomefloxacin can be decreased when it is combined with Iron Dextran.Approved, Vet Approved
IsoxicamIsoxicam may increase the neuroexcitatory activities of Lomefloxacin.Withdrawn
IstaroximeThe risk or severity of adverse effects can be increased when Istaroxime is combined with Lomefloxacin.Investigational
KebuzoneKebuzone may increase the neuroexcitatory activities of Lomefloxacin.Experimental
KetoprofenKetoprofen may increase the neuroexcitatory activities of Lomefloxacin.Approved, Vet Approved
KetorolacKetorolac may increase the neuroexcitatory activities of Lomefloxacin.Approved
LanreotideLomefloxacin may increase the hypoglycemic activities of Lanreotide.Approved
Lanthanum carbonateThe serum concentration of Lomefloxacin can be decreased when it is combined with Lanthanum carbonate.Approved
LeflunomideLeflunomide may increase the neuroexcitatory activities of Lomefloxacin.Approved, Investigational
LidocaineThe metabolism of Lomefloxacin can be decreased when combined with Lidocaine.Approved, Vet Approved
LiraglutideLomefloxacin may increase the hypoglycemic activities of Liraglutide.Approved
LisofyllineLisofylline may increase the neuroexcitatory activities of Lomefloxacin.Investigational
LornoxicamLornoxicam may increase the neuroexcitatory activities of Lomefloxacin.Approved
LoxoprofenLoxoprofen may increase the neuroexcitatory activities of Lomefloxacin.Approved
LumiracoxibLumiracoxib may increase the neuroexcitatory activities of Lomefloxacin.Approved, Investigational
MagaldrateMagaldrate can cause a decrease in the absorption of Lomefloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Withdrawn
Magnesium carbonateMagnesium carbonate can cause a decrease in the absorption of Lomefloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Magnesium hydroxideMagnesium hydroxide can cause a decrease in the absorption of Lomefloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Magnesium oxideMagnesium oxide can cause a decrease in the absorption of Lomefloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Magnesium salicylateThe serum concentration of Lomefloxacin can be decreased when it is combined with Magnesium salicylate.Approved
Magnesium SulfateThe serum concentration of Lomefloxacin can be decreased when it is combined with Magnesium Sulfate.Approved, Vet Approved
Magnesium TrisilicateMagnesium Trisilicate can cause a decrease in the absorption of Lomefloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
MasoprocolMasoprocol may increase the neuroexcitatory activities of Lomefloxacin.Approved
ME-609The risk or severity of adverse effects can be increased when ME-609 is combined with Lomefloxacin.Investigational
MecaserminLomefloxacin may increase the hypoglycemic activities of Mecasermin.Approved, Investigational
Meclofenamic acidMeclofenamic acid may increase the neuroexcitatory activities of Lomefloxacin.Approved, Vet Approved
MedrysoneThe risk or severity of adverse effects can be increased when Medrysone is combined with Lomefloxacin.Approved
Mefenamic acidMefenamic acid may increase the neuroexcitatory activities of Lomefloxacin.Approved
MelengestrolThe risk or severity of adverse effects can be increased when Melengestrol is combined with Lomefloxacin.Vet Approved
MeloxicamMeloxicam may increase the neuroexcitatory activities of Lomefloxacin.Approved, Vet Approved
MesalazineMesalazine may increase the neuroexcitatory activities of Lomefloxacin.Approved
MetamizoleMetamizole may increase the neuroexcitatory activities of Lomefloxacin.Withdrawn
MetforminLomefloxacin may increase the hypoglycemic activities of Metformin.Approved
MethylprednisoloneThe risk or severity of adverse effects can be increased when Methylprednisolone is combined with Lomefloxacin.Approved, Vet Approved
MexiletineThe metabolism of Lomefloxacin can be decreased when combined with Mexiletine.Approved
MifepristoneLomefloxacin may increase the hypoglycemic activities of Mifepristone.Approved, Investigational
MiglitolLomefloxacin may increase the hypoglycemic activities of Miglitol.Approved
MizoribineMizoribine may increase the neuroexcitatory activities of Lomefloxacin.Investigational
MometasoneThe risk or severity of adverse effects can be increased when Mometasone is combined with Lomefloxacin.Approved, Vet Approved
Mycophenolate mofetilMycophenolate mofetil may increase the neuroexcitatory activities of Lomefloxacin.Approved, Investigational
Mycophenolic acidThe serum concentration of Mycophenolic acid can be decreased when it is combined with Lomefloxacin.Approved
NabumetoneNabumetone may increase the neuroexcitatory activities of Lomefloxacin.Approved
NafamostatNafamostat may increase the neuroexcitatory activities of Lomefloxacin.Investigational
NaftifineNaftifine may increase the neuroexcitatory activities of Lomefloxacin.Approved
NaproxenNaproxen may increase the neuroexcitatory activities of Lomefloxacin.Approved, Vet Approved
NateglinideLomefloxacin may increase the hypoglycemic activities of Nateglinide.Approved, Investigational
NCX 1022The risk or severity of adverse effects can be increased when NCX 1022 is combined with Lomefloxacin.Investigational
NCX 4016NCX 4016 may increase the neuroexcitatory activities of Lomefloxacin.Investigational
NepafenacNepafenac may increase the neuroexcitatory activities of Lomefloxacin.Approved
NevirapineThe metabolism of Lomefloxacin can be decreased when combined with Nevirapine.Approved
Niflumic AcidNiflumic Acid may increase the neuroexcitatory activities of Lomefloxacin.Approved
NimesulideNimesulide may increase the neuroexcitatory activities of Lomefloxacin.Approved, Withdrawn
NitroaspirinNitroaspirin may increase the neuroexcitatory activities of Lomefloxacin.Investigational
OctreotideLomefloxacin may increase the hypoglycemic activities of Octreotide.Approved, Investigational
Oleoyl estroneThe risk or severity of adverse effects can be increased when Oleoyl estrone is combined with Lomefloxacin.Investigational
OlopatadineOlopatadine may increase the neuroexcitatory activities of Lomefloxacin.Approved
OlsalazineOlsalazine may increase the neuroexcitatory activities of Lomefloxacin.Approved
OrgoteinOrgotein may increase the neuroexcitatory activities of Lomefloxacin.Vet Approved
OsimertinibThe serum concentration of Lomefloxacin can be decreased when it is combined with Osimertinib.Approved
OuabainOuabain may decrease the cardiotoxic activities of Lomefloxacin.Approved
OxaprozinOxaprozin may increase the neuroexcitatory activities of Lomefloxacin.Approved
OxyphenbutazoneOxyphenbutazone may increase the neuroexcitatory activities of Lomefloxacin.Withdrawn
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Lomefloxacin.Approved, Vet Approved
ParamethasoneThe risk or severity of adverse effects can be increased when Paramethasone is combined with Lomefloxacin.Approved
ParecoxibParecoxib may increase the neuroexcitatory activities of Lomefloxacin.Approved
PasireotideLomefloxacin may increase the hypoglycemic activities of Pasireotide.Approved
Peginterferon alfa-2bThe serum concentration of Lomefloxacin can be increased when it is combined with Peginterferon alfa-2b.Approved
PentamidineLomefloxacin may increase the hypoglycemic activities of Pentamidine.Approved
PhenindioneLomefloxacin may increase the anticoagulant activities of Phenindione.Approved
PhenobarbitalThe metabolism of Lomefloxacin can be increased when combined with Phenobarbital.Approved
PhenprocoumonLomefloxacin may increase the anticoagulant activities of Phenprocoumon.Approved
PhenylbutazonePhenylbutazone may increase the neuroexcitatory activities of Lomefloxacin.Approved, Vet Approved
Picosulfuric acidThe therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Lomefloxacin.Approved
PimecrolimusPimecrolimus may increase the neuroexcitatory activities of Lomefloxacin.Approved, Investigational
PioglitazoneLomefloxacin may increase the hypoglycemic activities of Pioglitazone.Approved, Investigational
PirfenidonePirfenidone may increase the neuroexcitatory activities of Lomefloxacin.Investigational
PiroxicamPiroxicam may increase the neuroexcitatory activities of Lomefloxacin.Approved, Investigational
PramlintideLomefloxacin may increase the hypoglycemic activities of Pramlintide.Approved, Investigational
PrasteroneThe risk or severity of adverse effects can be increased when Prasterone is combined with Lomefloxacin.Approved, Nutraceutical
PrednicarbateThe risk or severity of adverse effects can be increased when Prednicarbate is combined with Lomefloxacin.Approved
PrednisoloneThe risk or severity of adverse effects can be increased when Prednisolone is combined with Lomefloxacin.Approved, Vet Approved
PrednisoneThe risk or severity of adverse effects can be increased when Prednisone is combined with Lomefloxacin.Approved, Vet Approved
PregnenoloneThe risk or severity of adverse effects can be increased when Pregnenolone is combined with Lomefloxacin.Experimental
PrimidoneThe metabolism of Lomefloxacin can be increased when combined with Primidone.Approved, Vet Approved
ProbenecidThe serum concentration of Lomefloxacin can be increased when it is combined with Probenecid.Approved
PropacetamolPropacetamol may increase the neuroexcitatory activities of Lomefloxacin.Approved
PTC299PTC299 may increase the neuroexcitatory activities of Lomefloxacin.Investigational
QuinaprilThe serum concentration of Lomefloxacin can be decreased when it is combined with Quinapril.Approved, Investigational
QuinineLomefloxacin may increase the hypoglycemic activities of Quinine.Approved
RepaglinideLomefloxacin may increase the hypoglycemic activities of Repaglinide.Approved, Investigational
ResveratrolResveratrol may increase the neuroexcitatory activities of Lomefloxacin.Experimental, Investigational
RifampicinThe metabolism of Lomefloxacin can be increased when combined with Rifampicin.Approved
RimexoloneThe risk or severity of adverse effects can be increased when Rimexolone is combined with Lomefloxacin.Approved
RofecoxibRofecoxib may increase the neuroexcitatory activities of Lomefloxacin.Investigational, Withdrawn
RopiniroleThe metabolism of Lomefloxacin can be decreased when combined with Ropinirole.Approved, Investigational
RosiglitazoneLomefloxacin may increase the hypoglycemic activities of Rosiglitazone.Approved, Investigational
SalicylamideSalicylamide may increase the neuroexcitatory activities of Lomefloxacin.Approved
Salicylic acidSalicylic acid may increase the neuroexcitatory activities of Lomefloxacin.Approved, Vet Approved
SalsalateSalsalate may increase the neuroexcitatory activities of Lomefloxacin.Approved
SaxagliptinLomefloxacin may increase the hypoglycemic activities of Saxagliptin.Approved
SeratrodastSeratrodast may increase the neuroexcitatory activities of Lomefloxacin.Approved, Investigational
SevelamerSevelamer can cause a decrease in the absorption of Lomefloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
SimeprevirThe metabolism of Lomefloxacin can be decreased when combined with Simeprevir.Approved
SitagliptinLomefloxacin may increase the hypoglycemic activities of Sitagliptin.Approved, Investigational
SRT501SRT501 may increase the neuroexcitatory activities of Lomefloxacin.Investigational
Strontium ranelateThe serum concentration of Lomefloxacin can be decreased when it is combined with Strontium ranelate.Approved
SucralfateThe serum concentration of Lomefloxacin can be decreased when it is combined with Sucralfate.Approved
SulfadiazineLomefloxacin may increase the hypoglycemic activities of Sulfadiazine.Approved, Vet Approved
SulfamethoxazoleLomefloxacin may increase the hypoglycemic activities of Sulfamethoxazole.Approved
SulfasalazineSulfasalazine may increase the neuroexcitatory activities of Lomefloxacin.Approved
SulfisoxazoleLomefloxacin may increase the hypoglycemic activities of Sulfisoxazole.Approved, Vet Approved
SulindacSulindac may increase the neuroexcitatory activities of Lomefloxacin.Approved
SunitinibLomefloxacin may increase the hypoglycemic activities of Sunitinib.Approved, Investigational
SuprofenSuprofen may increase the neuroexcitatory activities of Lomefloxacin.Approved, Withdrawn
TenofovirThe metabolism of Lomefloxacin can be decreased when combined with Tenofovir.Approved, Investigational
TenoxicamTenoxicam may increase the neuroexcitatory activities of Lomefloxacin.Approved
TepoxalinTepoxalin may increase the neuroexcitatory activities of Lomefloxacin.Vet Approved
TeriflunomideThe serum concentration of Lomefloxacin can be decreased when it is combined with Teriflunomide.Approved
TheophyllineThe metabolism of Theophylline can be decreased when combined with Lomefloxacin.Approved
Tiaprofenic acidTiaprofenic acid may increase the neuroexcitatory activities of Lomefloxacin.Approved
TiclopidineThe metabolism of Lomefloxacin can be decreased when combined with Ticlopidine.Approved
TinoridineTinoridine may increase the neuroexcitatory activities of Lomefloxacin.Investigational
TixocortolThe risk or severity of adverse effects can be increased when Tixocortol is combined with Lomefloxacin.Approved
TizanidineThe serum concentration of Tizanidine can be increased when it is combined with Lomefloxacin.Approved
TolazamideLomefloxacin may increase the hypoglycemic activities of Tolazamide.Approved
TolbutamideLomefloxacin may increase the hypoglycemic activities of Tolbutamide.Approved
Tolfenamic AcidTolfenamic Acid may increase the neuroexcitatory activities of Lomefloxacin.Approved
TolmetinTolmetin may increase the neuroexcitatory activities of Lomefloxacin.Approved
TranilastTranilast may increase the neuroexcitatory activities of Lomefloxacin.Approved, Investigational
TrastuzumabTrastuzumab may increase the cardiotoxic activities of Lomefloxacin.Approved, Investigational
TriamcinoloneThe risk or severity of adverse effects can be increased when Triamcinolone is combined with Lomefloxacin.Approved, Vet Approved
Trisalicylate-cholineTrisalicylate-choline may increase the neuroexcitatory activities of Lomefloxacin.Approved
ValdecoxibValdecoxib may increase the neuroexcitatory activities of Lomefloxacin.Investigational, Withdrawn
VareniclineThe serum concentration of Varenicline can be increased when it is combined with Lomefloxacin.Approved, Investigational
VemurafenibThe serum concentration of Lomefloxacin can be increased when it is combined with Vemurafenib.Approved
WarfarinLomefloxacin may increase the anticoagulant activities of Warfarin.Approved
ZaltoprofenZaltoprofen may increase the neuroexcitatory activities of Lomefloxacin.Approved
ZileutonZileuton may increase the neuroexcitatory activities of Lomefloxacin.Approved, Investigational, Withdrawn
ZomepiracZomepirac may increase the neuroexcitatory activities of Lomefloxacin.Withdrawn
Food InteractionsNot Available
References
Synthesis Reference

DrugSyn.org

US4528287
General ReferencesNot Available
External Links
ATC CodesJ01MA07S01AE04
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelDownload (88 KB)
MSDSNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9919
Blood Brain Barrier-0.9856
Caco-2 permeable-0.5416
P-glycoprotein substrateSubstrate0.8953
P-glycoprotein inhibitor INon-inhibitor0.8699
P-glycoprotein inhibitor IINon-inhibitor0.8383
Renal organic cation transporterNon-inhibitor0.7933
CYP450 2C9 substrateNon-substrate0.8591
CYP450 2D6 substrateNon-substrate0.9116
CYP450 3A4 substrateNon-substrate0.7284
CYP450 1A2 substrateNon-inhibitor0.9046
CYP450 2C9 inhibitorNon-inhibitor0.933
CYP450 2D6 inhibitorNon-inhibitor0.923
CYP450 2C19 inhibitorNon-inhibitor0.9025
CYP450 3A4 inhibitorNon-inhibitor0.8497
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.6283
Ames testAMES toxic0.9107
CarcinogenicityNon-carcinogens0.7701
BiodegradationNot ready biodegradable1.0
Rat acute toxicity1.9971 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.8282
hERG inhibition (predictor II)Non-inhibitor0.6392
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Pharmacia corp
Packagers
  • GD Searle LLC
  • Unimed Pharmaceuticals Inc.
Dosage formsNot Available
PricesNot Available
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point239-240.5 °CPhysProp
water solubility27.2 mg/mLNot Available
logP-0.30TAKACS-NOVAK,K ET AL. (1992)
Predicted Properties
PropertyValueSource
Water Solubility0.106 mg/mLALOGPS
logP0ALOGPS
logP-0.39ChemAxon
logS-3.5ALOGPS
pKa (Strongest Acidic)5.64ChemAxon
pKa (Strongest Basic)8.7ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count6ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area72.88 Å2ChemAxon
Rotatable Bond Count3ChemAxon
Refractivity90.11 m3·mol-1ChemAxon
Polarizability34.8 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as quinoline carboxylic acids. These are quinolines in which the quinoline ring system is substituted by a carboxyl group at one or more positions.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassQuinolines and derivatives
Sub ClassQuinoline carboxylic acids
Direct ParentQuinoline carboxylic acids
Alternative Parents
Substituents
  • Quinoline-3-carboxylic acid
  • N-arylpiperazine
  • Fluoroquinolone
  • Dihydroquinolone
  • Aminoquinoline
  • Dihydroquinoline
  • Pyridine carboxylic acid or derivatives
  • Pyridine carboxylic acid
  • Dialkylarylamine
  • Fluorobenzene
  • Benzenoid
  • Pyridine
  • Piperazine
  • 1,4-diazinane
  • Aryl halide
  • Aryl fluoride
  • Heteroaromatic compound
  • Vinylogous amide
  • Tertiary amine
  • Azacycle
  • Secondary amine
  • Monocarboxylic acid or derivatives
  • Secondary aliphatic amine
  • Carboxylic acid
  • Carboxylic acid derivative
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Organofluoride
  • Organohalogen compound
  • Carbonyl group
  • Amine
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External DescriptorsNot Available

Targets

Kind
Protein
Organism
Haemophilus influenzae (strain ATCC 51907 / DSM 11121 / KW20 / Rd)
Pharmacological action
yes
Actions
inhibitor
General Function:
Dna topoisomerase type ii (atp-hydrolyzing) activity
Specific Function:
DNA gyrase negatively supercoils closed circular double-stranded DNA in an ATP-dependent manner and also catalyzes the interconversion of other topological isomers of double-stranded DNA rings, including catenanes and knotted rings.
Gene Name:
gyrA
Uniprot ID:
P43700
Molecular Weight:
97817.145 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Takenouchi T, Ishii C, Sugawara M, Tokue Y, Ohya S: Incidence of various gyrA mutants in 451 Staphylococcus aureus strains isolated in Japan and their susceptibilities to 10 fluoroquinolones. Antimicrob Agents Chemother. 1995 Jul;39(7):1414-8. [PubMed:7492077 ]
  4. Drusano GL, Johnson DE, Rosen M, Standiford HC: Pharmacodynamics of a fluoroquinolone antimicrobial agent in a neutropenic rat model of Pseudomonas sepsis. Antimicrob Agents Chemother. 1993 Mar;37(3):483-90. [PubMed:8384815 ]
  5. Gushchin AE, Ladygina VG, Govorun VM: [Role of mutations in parC and gyrA in forming resistance of Mycoplasma hominis to fluoroquinolones]. Mol Gen Mikrobiol Virusol. 1999;(4):19-24. [PubMed:10621934 ]
Kind
Protein
Organism
Haemophilus influenzae (strain ATCC 51907 / DSM 11121 / KW20 / Rd)
Pharmacological action
yes
Actions
inhibitor
General Function:
Dna topoisomerase type ii (atp-hydrolyzing) activity
Specific Function:
Topoisomerase IV is essential for chromosome segregation. It relaxes supercoiled DNA. Performs the decatenation events required during the replication of a circular DNA molecule.
Gene Name:
parC
Uniprot ID:
P43702
Molecular Weight:
83366.24 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Didier ES, Bowers L, Stovall ME, Kuebler D, Mittleider D, Brindley PJ, Didier PJ: Antimicrosporidial activity of (fluoro)quinolones in vitro and in vivo. Folia Parasitol (Praha). 2005 May;52(1-2):173-81. [PubMed:16004377 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Ubiquitin binding
Specific Function:
Control of topological states of DNA by transient breakage and subsequent rejoining of DNA strands. Topoisomerase II makes double-strand breaks. Essential during mitosis and meiosis for proper segregation of daughter chromosomes. May play a role in regulating the period length of ARNTL/BMAL1 transcriptional oscillation (By similarity).
Gene Name:
TOP2A
Uniprot ID:
P11388
Molecular Weight:
174383.88 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Most active in catalyzing 2-hydroxylation. Caffeine is metabolized primarily by cytochrome CYP1A2 in the liver through an initial N...
Gene Name:
CYP1A2
Uniprot ID:
P05177
Molecular Weight:
58293.76 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Symporter activity
Specific Function:
Sodium-ion dependent, high affinity carnitine transporter. Involved in the active cellular uptake of carnitine. Transports one sodium ion with one molecule of carnitine. Also transports organic cations such as tetraethylammonium (TEA) without the involvement of sodium. Also relative uptake activity ratio of carnitine to TEA is 11.3.
Gene Name:
SLC22A5
Uniprot ID:
O76082
Molecular Weight:
62751.08 Da
References
  1. Ohashi R, Tamai I, Yabuuchi H, Nezu JI, Oku A, Sai Y, Shimane M, Tsuji A: Na(+)-dependent carnitine transport by organic cation transporter (OCTN2): its pharmacological and toxicological relevance. J Pharmacol Exp Ther. 1999 Nov;291(2):778-84. [PubMed:10525100 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Organic anion transmembrane transporter activity
Specific Function:
Mediates hepatobiliary excretion of numerous organic anions. May function as a cellular cisplatin transporter.
Gene Name:
ABCC2
Uniprot ID:
Q92887
Molecular Weight:
174205.64 Da
References
  1. Sasabe H, Tsuji A, Sugiyama Y: Carrier-mediated mechanism for the biliary excretion of the quinolone antibiotic grepafloxacin and its glucuronide in rats. J Pharmacol Exp Ther. 1998 Mar;284(3):1033-9. [PubMed:9495864 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23